Ceramedix is a growing, privately- and government- funded biopharmaceutical company developing a new class of endothelial tissue protection and repair medicines pioneered by leading scientific and clinical experts in these areas.
Our scientific founders at Memorial Sloan Kettering Cancer Center in New York and our Chief Scientific Officer have formed a deep, mechanistic understanding of a novel signaling biology that drives tissue injury in a broad range of medically relevant settings.
We believe our drug candidates will have application for treating multiple disease stresses that lead to organ failure, including those that affect the vascular endothelium of the eye, lung, kidney, and other organs. We are located in New York City.
Company Details
- Employees
- 6
- Founded
- 2020
- Address
- New York, New York 10013, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.ceramedix.com
- HQ
- New York, New York
Ceramedix, Inc. (Efl ‘25) Questions
Ceramedix, Inc. (Efl ‘25)'s website is http://www.ceramedix.com
Ceramedix, Inc. (Efl ‘25)'s LinkedIn profile is https://www.linkedin.com/company/ceramedix
Ceramedix, Inc. (Efl ‘25) has
6 employees.
View email and phone details for 6
employees at Ceramedix, Inc. (Efl ‘25).
Ceramedix, Inc. (Efl ‘25)'s industry is
Biotechnology Research
Ceramedix, Inc. (Efl ‘25)'s top competitors are
Nineteengale Therapeutics,
Metallomix Inc.,
Amplitude Therapeutics,
Indogulf Bioag,
Heppinn Biosciences,
Bluesphere Bio,
Mahajan Therapeutics,
Epibone, Inc.,
Echo Nyc,
Castlevax.
Ceramedix, Inc. (Efl ‘25)'s categories are Biotechnology Research
Ceramedix, Inc. (Efl ‘25)'s founding year is 2020
